Athens Research & Technology

Sorrento Therapeutics is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. Sorrento's lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical CAR-T therapies targeting solid tumors.

Redoxis is a preclinical boutique CRO specializing on inflammation and autoimmune conditions. We provide in vivo, ex vivo and in vitro preclinical efficacy and MoA studies. We have a fully equipped lab with capacity to perform a wide range of cell based assays as well as immunology assays to provide you everything form MoA studies to PK and in vivo efficacy studies.

Kinexus Bioinformatics Corporation maps and monitors the molecular communications networks of living cells for biomedical research into the diagnosis, prognosis and treatment of human diseases. In particular, the company tracks enzymes called protein kinases that control other proteins by carrying out their phosphorylation at regulatory sites known as phosphosites. Phosphosites act as on/off switches for proteins. Their malfunction has been linked to more than 400 human diseases, including cancer, cardiovascular disease, diabetes and inflammation.

Currently, Kinexus measures the presence and activation states of over 650 different protein kinases and other regulatory proteins and many of their phosphosites in cell and tissue specimens through our integrated platform of cell culture, protein microarray, immunoblotting, mass spectrometry and immunohistochemistry services.

These innovative proprietary services utilize unique and stringent screening methods to facilitate the discovery and validation of biomarkers, drug targets and the rapid exclusion of inappropriate drug leads in the early stages of the drug discovery process. This is further augmented by a suite of open source, online bioinformatics services that are offered by Kinexus. Our bioinformatics studies are helping us to create new tools for biomedical research that include enzymes, antibodies and peptides.

For over 12 years, Kinexus has provided our unique services to over 1600 laboratories in 35 countries.

Our company is recognized for excellence in providing ISO 9001monoclonal and polyclonal antibodies, antigens, enzymes, and purified proteins to the research and medical diagnostic marketplace. Nearly all of our products are validated for usage in quantitative sandwich immunoassay and qualitative rapid testing.

We offer immunological reagents worldwide for diagnostics & research in the following disciplines:

Infectious Diseases (60)
Neuroscience (45)
Inflammation (43)
Veterinary (41)
Cardiac Markers (36)
Gangliosides & Globosides (33)
Tumor Markers (26)
Hormones (22)
Microbial & Plant Toxins (21)
Metabolic Syndrome (15)
Blood Coagulation and Anemia (12)
Biodefense (10)
Kidney Diseases (4)
Fertility and Pregnancy (2)


We are happy to inform you that Advanced ImmunoChemical is now offering a set of antibodies produced In vitro. In addition, some of our current antibodies are now available both as In vivo- and In vitro-produced products.

Monoclonal antibodies and mammalian antigens for detecting infectious diseases, cardiac biomarkers, and hormones.

Broad selection antibodies and inactivated viral antigens to detect Influenza A and B in clinical samples.
Monoclonal antibodies for the detection of biological threats and dangerous pathogens.

Biomarkers for cardiovascular disease prevention, risk assessment, and diagnostics.

Customers Include: Princeton University, Duke University School of Medicine, Columbia University Medical Center, CDC, National Institutes of Health, Naval Health Research Center, Los Alamos National Laboratory, US Army Medical Research Institute of Infectious Diseases, Sandia National Laboratories, Stanfored Medicine, NIST, NIMH, Harvard Medical School, Yale University School of Medicine, John Hopkins School of Medicine, Lawrence Livermore National Laboratory, and many more!

Advanced ImmunoChemical is a WBENC-certified woman-owned small business, since 1986.

AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates to address emerging biological targets using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation in vitro. Our strategy is to advance the development and commercialization of our proprietary product candidates, and for certain programs, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights in the United States.

Our wholly-owned product pipeline includes etokimab (ANB020) and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. We are advancing etokimab, an antibody that inhibits the activity of interleukin-33, for the treatment of moderate-to-severe adult atopic dermatitis, severe adult eosinophilic asthma, and adult chronic rhinosinusitis with nasal polyps (CRSwNP).

In addition, we are developing our ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP).

Our company is led by a strong management team with a proven track record of successfully growing biotechnology companies with deep experience in antibody discovery and development, collaborations, operations and corporate finance.

Additionally, multiple AnaptysBio-generated antibodies have entered the clinic under our immuno-oncology-focused collaboration with TESARO and inflammation-focused collaboration with Celgene.

For more information, visit www.anaptysbio.com.